Table 2. Patients’ characteristics.

Clinical parameter	IK6-positive		IK6-negative		P value
	(n=20)		(n=22)
	N	%	N	%
Gender
Male	11	55	13	59.1	0.789
Female	9	45	9	40.9
Age(years)
18-39	10	50	12	54.5	0.918
40-64	6	30	7	31.8
≥65	4	20	3	13.6
White blood cells count (cells×109/L)
<30	4	20	15	68.2	0.005
30-100	6	30	4	18.2
>100	10	50	3	13.7
aEarly clinical response
Yes	6	30	15	68.2	0.013
No	14	70	7	31.8
BCR-ABL1
p190	11	55	14	63.6	0.569
p210	9	45	8	36.4
Imatinib exposure
Yes	13	65	16	72.7
No	7	35	6	27.3
bHSCT
Yes	4	20	7	31.8
No	16	80	15	68.2
cMRD risk group
Standard risk	4	20	12	54.5	0.036
Intermediate risk	9	45	8	36.4
High risk	7	35	2	9.1

^aEarly clinical response was defined as≤5% leukemic blast cells in the bone marrow at day 21 (depending on national induction protocols).

^bHSCT, hematopoietic stem cell transplantation.

^cMinimal residual disease (MRD), standard risk: negative after induction therapy on treatment day 33 and consolidation therapy on treatment day 78, high risk: still positive at an MRD level of ≥10³ after consolidation therapy on treatment day 78, intermediate risk: all others.